Skip to content
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Heart icon (animated) heart icon (static)
Our Stories
Our Company
Follow Us
Explore more Johnson & Johnson sites:
Australia
A graphic of the flag of Australia alt
Argentina
A graphic of the flag of Argentina alt
Brazil
A graphic of the flag of Brazil alt
Canada
A graphic of the national flag of Canada alt
Chile
A graphic of the flag of Chile alt
China
A graphic of the national flag of the People's Republic of China alt
Colombia
A graphic of the national flag of Colombia alt
Costa Rica
A graphic of the national flag of Costa Rica alt
Czech Republic
Ecuador
A graphic of the national flag of Ecuador alt
Germany
A graphic of the flag of Germany alt
India
A graphic of the national flag of India alt
Japan
A graphic of the national flag of Japan alt
Mexico
A graphic of the flag of Mexico alt
New Zealand / Pacific
A graphic of the flag of New Zealand alt
Paraguay
A graphic of the flag of Paraguay alt
Peru
A graphic of the flag of Peru alt
Philippines
A graphic of the national flag of the Philippines alt
Russia
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
German
English
French
United Kingdom
A graphic of the national flag of the U.K. alt
United States
A graphic of the flag of the United States of America alt
Uruguay
A graphic of the national flag of Uruguay alt
Venezuela
A graphic of the flag of Venezuela alt
Share

Pharmaceutical Pipeline

Download Report

Janssen Pharmaceutical Companies of Johnson & Johnson Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings* (2019-2023 Key Filings, As Outlined at 2019 Pharm Business Review)

Selective Highlights as of July 21, 2021

NME's APPROVED

Infectious Diseases and Vaccines

Janssen COVID-19 Vaccine

COVID-19
EUA US
cMAA EU

Monovalent Ebola Vaccine

Ebola virus Disease
EU
Neuroscience

PONVORY (ponesimod)

Relapsing forms of multiple sclerosis

SPRAVATO (esketamine)

Treatment resistant depression
Oncology

BALVERSA (erdafitinib)

Urothelial cancer
US

ERLEADA (apalutamide)

Non-metastatic prostate cancer
EU

RYBREVANT (amivantamab)

Non Small Cell Lung Cancer
US

NME's in REGISTRATION

Oncology

ciltacabtagene autoleucel (BCMA CAR-T)

Relapsed refractory Multiple Myeloma

RYBREVANT (amivantamab)

Non Small Cell Lung Cancer
EU

NME PLANNED FILINGS 2021-2023

Cardiovascular and Metabolism

aprocitentan

Difficult to treat hypertension

RPGR AAV Gene Therapy

X-linked retinitis pigmentosa
Immunology

​nipocalimab

Warm Autoimmune Hemolytic Anemia
Infectious Diseases and Vaccines

RSV Sr. vaccine

RSV vaccine
Neuroscience

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms
Oncology

BALVERSA (erdafitinib)

Urothelial cancer
EU

niraparib

Metastatic castration-resistant prostate cancer (mCRPC)

talquetamab (GPRC5D/CD3)

Multiple myeloma

teclistamab (BCMA/CD3)

Multiple myeloma
Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information. BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab); Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue